However, molecular targeting of EGFR with monoclonal antibodies such as cetuximab, a Food and Drug Administration (FDA)-approved strategy in HNSCC, has only yielded a moderate patient response rate, ranging from 10 to 30% when used as a monotherapy [7,8,9]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.